Figure 4.
The β-catenin activator, SB-216763, inhibits pirfenidone (PFD) effects in HepG2 cells. (A) Apoptosis was detected by flow cytometry in HepG2 cells treated with PFD (600 μmol/L) with and without SB-216763. (B) The extent of apoptosis was quantified in HepG2 cells treated with PFD (600 μmol/L) with and without SB-216763. (C) Colony formation assays were performed in HepG2 cells treated with PFD (600 μmol/L) with and without SB-216763. (D) The number of colonies was determined. (** P<0.01).